CN108379252B - 醋栗花青素在制备抗肝纤维化药品或保健品中的应用 - Google Patents
醋栗花青素在制备抗肝纤维化药品或保健品中的应用 Download PDFInfo
- Publication number
- CN108379252B CN108379252B CN201810258014.1A CN201810258014A CN108379252B CN 108379252 B CN108379252 B CN 108379252B CN 201810258014 A CN201810258014 A CN 201810258014A CN 108379252 B CN108379252 B CN 108379252B
- Authority
- CN
- China
- Prior art keywords
- gooseberry
- anthocyanidin
- liver
- hepatic fibrosis
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000002357 Ribes grossularia Nutrition 0.000 title claims abstract description 40
- 150000001452 anthocyanidin derivatives Chemical class 0.000 title claims abstract description 30
- 229930014669 anthocyanidin Natural products 0.000 title claims abstract description 28
- 235000008758 anthocyanidins Nutrition 0.000 title claims abstract description 28
- 239000003814 drug Substances 0.000 title claims abstract description 22
- 229940079593 drug Drugs 0.000 title claims abstract description 19
- 206010019668 Hepatic fibrosis Diseases 0.000 title claims abstract description 15
- 244000171263 Ribes grossularia Species 0.000 title abstract description 33
- 230000036541 health Effects 0.000 title abstract description 12
- 230000000694 effects Effects 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims abstract description 10
- 239000002552 dosage form Substances 0.000 claims abstract description 4
- 241000203102 Byrsonima lucida Species 0.000 claims abstract 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- VEVZSMAEJFVWIL-UHFFFAOYSA-O cyanidin cation Chemical compound [O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC=C(O)C(O)=C1 VEVZSMAEJFVWIL-UHFFFAOYSA-O 0.000 claims description 10
- 235000019441 ethanol Nutrition 0.000 claims description 6
- 235000007336 cyanidin Nutrition 0.000 claims description 5
- 235000013399 edible fruits Nutrition 0.000 claims description 5
- 239000011347 resin Substances 0.000 claims description 5
- 229920005989 resin Polymers 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 4
- 239000002250 absorbent Substances 0.000 claims description 3
- 230000002745 absorbent Effects 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 238000002604 ultrasonography Methods 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940100688 oral solution Drugs 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 238000005057 refrigeration Methods 0.000 claims 1
- 238000002390 rotary evaporation Methods 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract description 23
- 230000002265 prevention Effects 0.000 abstract description 6
- 239000002994 raw material Substances 0.000 abstract description 3
- 210000004185 liver Anatomy 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 8
- 108010082126 Alanine transaminase Proteins 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 241001529936 Murinae Species 0.000 description 6
- 210000005228 liver tissue Anatomy 0.000 description 6
- 206010016654 Fibrosis Diseases 0.000 description 5
- 230000002440 hepatic effect Effects 0.000 description 5
- 210000005229 liver cell Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 230000004761 fibrosis Effects 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 3
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 3
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 2
- GCPYCNBGGPHOBD-UHFFFAOYSA-N Delphinidin Natural products OC1=Cc2c(O)cc(O)cc2OC1=C3C=C(O)C(=O)C(=C3)O GCPYCNBGGPHOBD-UHFFFAOYSA-N 0.000 description 2
- OIZFQAFWYYKPMR-PEVLUNPASA-N Delphinidin 3-O-glucoside Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C=1[C-](c2cc(O)c(O)c(O)c2)[O+]c2c(c(O)cc(O)c2)C=1 OIZFQAFWYYKPMR-PEVLUNPASA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- IKGXIBQEEMLURG-UHFFFAOYSA-N Rutin Chemical compound OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229950005499 carbon tetrachloride Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- JKHRCGUTYDNCLE-UHFFFAOYSA-O delphinidin Chemical compound [O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC(O)=C(O)C(O)=C1 JKHRCGUTYDNCLE-UHFFFAOYSA-O 0.000 description 2
- 235000007242 delphinidin Nutrition 0.000 description 2
- XENHPQQLDPAYIJ-PEVLUNPASA-O delphinidin 3-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC2=C(O)C=C(O)C=C2[O+]=C1C1=CC(O)=C(O)C(O)=C1 XENHPQQLDPAYIJ-PEVLUNPASA-O 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- GXPTVXHTZZVLMQ-GCGJSEPQSA-N myrtillin Natural products O[C@H]1O[C@@H](OCC2=C(OC3=CC(=O)C=C(O)C3=C2)c4cc(O)c(O)c(O)c4)[C@H](O)[C@@H](O)[C@@H]1O GXPTVXHTZZVLMQ-GCGJSEPQSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 2
- 235000005493 rutin Nutrition 0.000 description 2
- 229960004555 rutoside Drugs 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000009777 vacuum freeze-drying Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000064622 Physalis edulis Species 0.000 description 1
- 235000001982 Physalis edulis Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 235000016951 Ribes missouriense Nutrition 0.000 description 1
- 241000735885 Ribes missouriense Species 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000009243 biejia ruangan Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- USNPULRDBDVJAO-FXCAAIILSA-N cyanidin 3-O-rutinoside betaine Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(=[O+]C3=CC(O)=CC([O-])=C3C=2)C=2C=C(O)C(O)=CC=2)O1 USNPULRDBDVJAO-FXCAAIILSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000021022 fresh fruits Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 229960001331 keracyanin Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 238000004506 ultrasonic cleaning Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
- C07D311/62—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2 with oxygen atoms directly attached in position 3, e.g. anthocyanidins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
本发明涉及醋栗花青素在制备抗肝纤维化药品或保健品中的应用。采用醋栗花青素作为原料，单用或与其他具有抗肝纤维化作用的药物组合，按常规制剂的制备方法，制备成适合口服的任何剂型的抗肝纤维化药品或保健品。醋栗花青素具有很强的预防肝纤维化的能力。
Description
技术领域
本发明属于保健食品和药物领域，具体地涉及醋栗花青素在制备具有预防肝纤维化的药品或保健品中的应用。
背景技术
肝纤维化(fibrosis of liver)是多种原因引起的慢性肝损害所致的病理改变，表现为肝内细胞外间质成分过度异常地沉积，并影响肝脏的功能，是慢性肝病发展到肝硬化必经之阶段。现认为肝纤维化尚有逆转至正常的可能，而肝硬化则否。目前研究的重点放在分子与分子、分子与细胞及细胞与细胞间的相互作用方面。在诊治方面虽然有一些进展，但仍缺乏确定有效的药物。
肝纤维化保健品能在一定程度上预防肝纤维化，促进身体健康，减少肝损伤。目前抗肝纤维化药物可以分为传统中药和现代药物两大类。例如安络化纤丸、复方鳖甲软肝片等药物，能软坚散结，化瘀解毒，益气养血，疏通肝血流、清除肝内淤积、降低门静脉压、防止出血、促使肝纤维降解吸收和阻断肝内纤维增生，预防、阻断和逆转肝纤维化。而化学合成的药物，其成本大，毒性大，副作用强，会影响内分泌功能和消化道反应等副作用。因此，从天然植物中寻找具有生物活性的、预防肝纤维化作用的物质应用于医药、食品和保健品中具有重要的意义。
醋栗又名灯笼果，拉丁文名：Ribes missouriense。醋栗酸甜可口，营养丰富，富含维C和胡萝卜素。醋栗是一种药用植物，广泛应用于预防和治疗癌症、白血病、抑菌、利尿、抗炎及免疫调节。醋栗蕴含丰富的花青素，花青素在鲜果中的相对含量为0.1％，醋栗提取物对人肝癌细胞HepG-2有较好的抑制作用。醋栗是东北重要经济树种之一，果实香甜可食，可做罐头、果酱、酿酒、饮料等，具有很高的经济价值，还可作观赏树种，加工特性适宜，是具有前途的功能性食品原材料。
发明内容
本发明以寻求新型高效的预防肝纤维化药品或保健品的开发利用为目的，提出了醋栗花青素在制备预防肝纤维化作用的药品或保健品中的应用。
本发明采用醋栗花青素作为原料，单用或与其他具有抗肝纤维化作用的药物组合，按常规制剂的制备方法，制备成适合口服的任何剂型的抗肝纤维化药品或保健品，如口服液，片剂，胶囊，颗粒剂，或其它针剂剂型。
优选的，所述的醋栗花青素是醇提化合物。
优选的，醋栗花青素的制备方法包括如下步骤：60-70℃下，将醋栗果实置于乙醇中浸泡1-2h后，超声30min，连续超声2次，产物经大孔吸附树脂纯化后，所得提取液旋转蒸发，浓缩，真空冷冻干燥，得醋栗花青素提取物。
更优选的，所述的乙醇为体积百分浓度为60％的乙醇。所述的大孔吸附树脂为大孔吸附树脂AB-8。
本发明的有益效果是：本发明采用的是醋栗花青素，以四氯化碳诱导的方式诱导小鼠快速肝纤维化，通过肝纤维化模型小鼠体内实验得出，醋栗花青素可以降低肝纤维化小鼠的脏器指数，以及肝纤维化标志性酶即血清和肝脏组织中谷草转氨酶和谷丙转氨酶含量下降，并维持小鼠肝组织结构完整清晰，肝细胞大小均匀，无变性、坏死、细胞核大而圆，多居于细胞中央。因此，醋栗花青素具有抗肝纤维化的功效，是开发新型高效的天然抗肝纤维化药物或保健品的一个好选择。
附图说明
图1是各组小鼠肝系数的比较结果。
图2A是各组小鼠血清中谷草转氨酶(AST/GOT)含量比较结果。
图2B是各组小鼠血清中谷丙转氨酶(ALT/GPT)含量比较结果。
图3A是各组小鼠肝组织中谷草转氨酶(AST/GOT)含量比较结果。
图3B是各组小鼠肝组织中谷丙转氨酶(ALT/GPT)含量比较结果。
图4是各组小鼠肝组织HE染色情况比较图。
具体实施方式
实施例1
(一)制备方法
醋栗花青素提取物的制备：称取醋栗果实100g，用60％的乙醇在60-70℃浸泡1h，放入超声清洗器中超声30min，连续2次，经大孔吸附树脂AB-8纯化后，再用旋转蒸发仪浓缩提取液，经过真空冷冻干燥得醋栗花青素干粉。
经检测醋栗花青素主要单体成分为，矢车菊素3-O-葡萄糖苷(cyanidin 3-O-glucoside)、矢车菊素3-O-芸香苷(cyanidin 3-O-rutinoside)、飞燕草素3-O-葡萄糖苷(delphinidin 3-O-glucoside)、飞燕草素3-O-芸香苷(delphinidin 3-O-rutinoside)。
(二)药效试验
动物饲养及处理：实验动物饲养1周以适应本实验室条件，分笼饲养，室内无菌消毒，每两天换一次垫料。控制实验室光照12h明-12h暗，室内温度为20±1℃，湿度为55±10％。
实验动物分组：雄性小鼠50只，体重30±2g，随机分为5组如下，每组10只。
(1)正常对照组(C)；
(2)肝纤维化模型组(M)；
(3)阳性对照组(E)；
(4)给药组：醋栗花青素组70mg/L(H)；
(5)给药组：醋栗花青素组35mg/L(L)
正常对照组10只小鼠皮下注射生理盐水，其余小鼠注射20％四氯化碳橄榄油混合液(150mg/kg)，每日一次，持续8周。造模的同时进行给药，除正常对照组、肝纤维化模型组小鼠给予生理盐水饮水外，给药组小鼠分别给予醋栗花青素35mg/L和70mg/L，每一周称量并记录小鼠体重。实验8周时，进行检测。
1.采血后处死小鼠，收集肝组织并称重，计算肝系数。肝系数的比较结果见图1。
如图1所示，肝纤维化模型组小鼠肝系数明显高于正常组(p<0.01)，醋栗花青素给药能干预肝纤维化引起的肝系数升高，相较于肝纤维化模型组，给药组H可以显著抑制小鼠肝系数的升高(p<0.01)。实验结果说明醋栗花青素对于小鼠肝纤维化过程中肝增大具有显著的干预作用且呈剂量相关性。
2.检测血清和肝组织内谷草转氨酶(AST/GOT)和谷丙转氨酶(ALT/GPT)的含量，结果见图2A，图2B，图3A和图3B。
如图2A和图2B所示，肝纤维化模型组小鼠血清的谷草转氨酶(AST/GOT)和谷丙转氨酶(ALT/GPT)的含量明显高于正常组，醋栗花青素给药可以降低肝纤维化模型小鼠血清的谷草转氨酶(AST/GOT)和谷丙转氨酶(ALT/GPT)的含量，且其对含量的降低具有显著性(给药组L为p<0.05，给药组H为p<0.001)。实验结果说明醋栗花青素对小鼠肝纤维化过程中血清中谷草转氨酶(AST/GOT)和谷丙转氨酶(ALT/GPT)的含量具有一定的干预作用，并且呈剂量相关性。
如图3A和图3B所示，肝纤维化模型组小鼠肝组织中的谷草转氨酶(AST/GOT)和谷丙转氨酶(ALT/GPT)的含量明显高于正常组，醋栗花青素给药可以降低肝纤维化模型小鼠肝组织中的谷草转氨酶(AST/GOT)和谷丙转氨酶(ALT/GPT)的含量，且其对含量的降低具有显著性(给药组L为p<0.05，给药组H为p<0.001)。实验结果说明醋栗花青素对小鼠肝纤维化过程中肝组织中谷草转氨酶(AST/GOT)和谷丙转氨酶(ALT/GPT)的含量具有一定的干预作用，并且呈剂量相关性。
3.HE染色观察肝纤维化小鼠肝组织的结构和形态，结果见图4。
如图4所示，HE切片结果显示，空白对照组小鼠肝脏标本肝小叶结构正常，肝细胞索排列规则，肝细胞无变性、坏死，未见增生纤维组织。肝纤维化模型组小鼠肝细胞排列欠规则，有部分肝细胞坏死、脂肪变性及气球样变，汇管区纤维化扩大，窦周可见少许纤维组织增生，汇管区可见线状短纤维间隔形成。醋栗花青素给药组,肝细胞变性无坏死，汇管区纤维沉积较模型组明显减少，略有炎症浸润，其中高剂量给药组更具显著性的影响。
Claims (2)
1.醋栗花青素在制备抗肝纤维化药品中的应用，其特征在于，醋栗花青素单用或与其他具有抗肝纤维化作用的药物组合制备抗肝纤维化药品；所述的醋栗花青素的制备方法包括如下步骤：60-70℃下，将醋栗果实置于体积百分浓度为60%的乙醇中浸泡1-2 h后，超声30min，连续2次，产物经大孔吸附树脂AB-8纯化后，所得提取液旋转蒸发，浓缩，真空冷冻干燥，得醋栗花青素提取物。
2.根据权利要求1所述的应用，其特征在于，所述的药品制成口服液、片剂、胶囊、颗粒剂或针剂剂型。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810258014.1A CN108379252B (zh) | 2018-03-27 | 2018-03-27 | 醋栗花青素在制备抗肝纤维化药品或保健品中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810258014.1A CN108379252B (zh) | 2018-03-27 | 2018-03-27 | 醋栗花青素在制备抗肝纤维化药品或保健品中的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108379252A CN108379252A (zh) | 2018-08-10 |
| CN108379252B true CN108379252B (zh) | 2019-08-09 |
Family
ID=63072304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810258014.1A Active CN108379252B (zh) | 2018-03-27 | 2018-03-27 | 醋栗花青素在制备抗肝纤维化药品或保健品中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108379252B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111419864B (zh) * | 2020-04-02 | 2023-09-15 | 辽宁大学 | 醋栗花色苷在制备诱导结肠癌细胞凋亡的药品中的应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100080821A1 (en) * | 2008-09-30 | 2010-04-01 | Sylmark, Inc. | Energy Compositions |
-
2018
- 2018-03-27 CN CN201810258014.1A patent/CN108379252B/zh active Active
Non-Patent Citations (2)
| Title |
|---|
| 花色苷对酒精性肝病的防治作用及机制;万婷等;《华南预防医学》;20170430;第43卷(第2期);第187-190页，尤其是第189页左栏第1段 * |
| 西印度醋栗对四氯化碳引起的大鼠和小鼠急性过氧化肝损伤的保护作用;Nilesh Kumar Jain等;《中西医结合学报》;20110131;第9卷(第1期);第49-56页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108379252A (zh) | 2018-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103844143B (zh) | 罗非鱼用预防链球菌病复方中草药饲料添加剂 | |
| CN105147717B (zh) | 桦褐孔菌多糖组分在防治慢性胰腺炎中的应用 | |
| CN104922176B (zh) | 一种野菊花提取物的应用 | |
| KR100699790B1 (ko) | 댕댕이나무 추출물을 포함하는 간 질환 예방 및 치료효과를 가지는 약제학적 조성물 | |
| CN112057546A (zh) | 一种蜂胶灵芝孢子粉组合物及其制备方法和应用 | |
| CN108310080A (zh) | 黑果腺肋花楸花色苷在制备抗肝纤维化药品或保健品中的应用 | |
| CN104013636B (zh) | 瓦草五环三萜皂苷类化合物抗肿瘤的药物用途 | |
| CN108379252B (zh) | 醋栗花青素在制备抗肝纤维化药品或保健品中的应用 | |
| CN100522184C (zh) | 具有抗肿瘤和抗毒活性的提取物 | |
| CN103989724B (zh) | 降血糖的保健食品及其制备方法 | |
| CN107648297A (zh) | 一种黄褐毛忍冬提取物、含有该提取物的制剂及在医药领域的应用 | |
| CN113694104B (zh) | 一种对化学性肝损伤有保护作用、促进肝脏再生的中药组合物、制备方法及其用途 | |
| CN106361983A (zh) | 一种辅助治疗糖尿病的胶囊剂及其制备方法 | |
| CN109602759A (zh) | 罗汉松实多糖的用途 | |
| KR20200069965A (ko) | 도토리 화분 추출물을 유효성분으로 함유하는 혈전증의 예방 또는 치료용 약학적 조성물 및 건강 기능 식품 | |
| US20100074975A1 (en) | Pharmaceutical composition for the prevention and treatment of liver disease comprising a lonicera caerulea L. Var. Edulis extract | |
| CN104286844A (zh) | 一种提高免疫力的食品、保健品或药物组合物 | |
| CN104644734A (zh) | 一种治疗ⅱ型糖尿病及其并发症的药物 | |
| CN104042928B (zh) | 一种治疗糖尿病的药物组合物及其制备方法和用途 | |
| CN108570116B (zh) | 黄绿卷毛菇多糖及制备方法和在防治糖尿病中的医用用途 | |
| CN110101732A (zh) | 具有改善肠道功能的菊茎叶多成分颗粒剂及其制备方法与应用 | |
| CN113181173B (zh) | 药用组合物及其在制备用于预防和/或治疗肝癌的产品中的应用 | |
| CN107582782A (zh) | 一种含槟榔成分的药物制备方法及其抗缺氧应用 | |
| CN108310002A (zh) | 一种预防和/或治疗血管损伤疾病的组合物及其用途 | |
| CN108685978A (zh) | 一种用于提高免疫力的中药提取物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20221104 Address after: 276800 1st floor, building 2, new generation information technology industrial park, high tech Zone, Rizhao City, Shandong Province Patentee after: Shandong Kaipu fite Biotechnology Co.,Ltd. Address before: 110000 58 Shenbei New Area Road South, Shenyang, Liaoning. Patentee before: LIAONING University |
|
| TR01 | Transfer of patent right |